TMEM65 and neoplasm: To validate the relevance of our findings to human CRC and to further examine whether hindering CHD6-TMEM65 signaling axis can control the capacity of tumor formation in human CRC, we established PDXs40 by implanting primary tumor samples resected from CRC patients into the immunocompromised mice.